Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies
Frontiers in Pharmacology · 13.02.2024 · 15
DOI: 10.3389/fphar.2024.1335058 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.02.2024. Verfasst von Feda E Mohamed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gaucher disease (GD) is mainly caused by glucocerebrosidase (GCase) enzyme deficiency due to genetic variations in the GBA1 gene leading to the toxic accumulation of sphingolipids in various organs, which causes symptoms such as anemia, thrombocytopenia, hepatosplenomegaly, and neurological manifestations. GD is clinically classified into the non-neuronopathic type 1, and the acute and chronic neuronopathic forms, types 2 and 3, respectively. In addition to the current approved GD medications, the repurposing of Ambroxol (ABX) has emerged as a prospective enzyme enhancement therapy option showing its potential to enhance mutated GCase activity and reduce glucosylceramide accumulation in GD-affected tissues of different GBA1 genotypes. The variability in response to ABX varies across different variants, highlighting the diversity in patients’ therapeutic outcomes. Its oral availability and safety profile make it an attractive option, particularly for patients with neurological manifestations. Clinical trials are essential to explore further ABX’s potential as a therapeutic medication for GD to encourage pharmaceutical companies’ investment in its development. This review highlights the potential of ABX as a pharmacological chaperone therapy for GD and stresses the importance of addressing response variability in clinical studies to improve the management of this rare and complex disorder.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Abu Dhabi, United Arab Emirates.
- Department of Pediatrics, Tawam Hospital, Al Ain, United Arab Emirates.
Zitieren
APA
Mohamed, F. E., & Al-Jasmi, F. (2024). Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1335058
Vancouver
Mohamed FE, Al-Jasmi F. Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1335058
BibTeX
@article{Mohamed2024,
author = {Mohamed, Feda E and Al-Jasmi, Fatma},
title = {Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1335058}
}
EUVIMED